Mar 31, 2015 8:00 am EDT Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure
Mar 23, 2015 8:05 am EDT Capricor Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25, 2015 in New York
Mar 18, 2015 4:05 pm EDT Capricor Therapeutics Reports Fourth Quarter and Full Year 2014 Financial & Business Highlights
Mar 12, 2015 8:00 am EDT Capricor Therapeutics to Hold Fourth Quarter 2014 Business Update Conference Call on March 18, 2015 at 4:30 p.m. EDT
Mar 05, 2015 9:00 am EST Capricor Announces Enrollment of Its Phase II Clinical Trial for Cenderitide to Treat Heart Failure
Feb 27, 2015 9:00 am EST Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development
Feb 04, 2015 9:00 am EST Capricor Therapeutics Announces $7 Million Private Placement of Common Stock
Jan 21, 2015 8:00 am EST Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET